v3.25.1
Business Combinations (Tables)
 3 Months Ended
Mar. 31, 2025
Business Combinations [Abstract]  
Schedule of Business Combinations

Details of business combinations that occurred for the three months ended March 31, 2025 and 2024 are as follows:

 

      For the year ended December 31, 2023
Acquiree  Main business  Acquisition date  Ownership
(%)		   Total
consideration		 
Darnatein  New drug development, etc.  March 31, 2023   100.0%  $81,436,889 
Schedule of Identifiable Assets and Liabilities and Goodwill

Details of identifiable assets and liabilities and goodwill, which are recognized as the result of the acquisition of Darnatein completed during the year ended December 31, 2023 are set forth in the table below.

 

   Darnatein 
Fair value of total identifiable assets:    
Current assets:    
Cash and cash equivalents  $68,600 
Trade and other receivables   4,338 
Current tax assets   285 
Non-current assets:     
Equipment and vehicles   7,307 
Right-of-use assets   73,114 
Intangible assets   73,948,145 
Non-current financial assets   1,101 
    74,102,891 
Fair value of total identifiable liabilties:     
Current liabilities:     
Trade and other payables   70,240 
Lease liabilities   33,612 
Current other liabilities   6,497 
Non-current liabilities:     
Severance payment   1,889 
Lease liabilities   58,784 
Deferred tax liabilities   19,407,543 
    19,578,565 
Fair value of identifiable net assets   54,524,326 
Goodwill    26,912,563 
Purchase consideraation transferred (*)  $81,436,889 
(*1)OSR ordinary shares issued for purchase consideration of $81,436,889 is 590,425 shares at $138 per share. The number of OSR ordinary shares to be issued was determined based on negotiation with former owners of Darnatein.
Schedule of Unaudited Pro Forma Consolidated Results of Operations The following unaudited pro forma consolidated results of operations assume that the acquisition of Darnatein was completed as of January 1, 2023.
   (Unaudited) three months ended March 31, 
   2025   2024 
Total operating revenues  $
-
   $
-
 
Net loss attributable to OSR Holdings   (141,742)   (751,979,471)
Schedule of Patent Technology Recognized from the Acquisition of Darnatein

Details of patent technology recognized from the acquisition of Darnatein that occurred during the year ended December 31, 2023 are set forth in the table below.

 

    Amount 
Patent technology project code:      
DRT 101  $73,513,419 
Schedule of Net Cashflow from the Acquisitions

Net cashflow from the acquisitions for the three months ended March 31, 2025 and 2024 are as follows:

 

    2025 
Net cash outflow arising from acquisition of Darnatein:     
Cash consideration  $
-
 
Less: cash and cash equivalent balances acquired   
-
 
   $         - 

 

    2024 
Net cash outflow arising from acquisition of VAXIMM and RMC:     
Cash consideration  $-  
Less: cash and cash equivalent balances acquired   
-
 
   $         -